[go: up one dir, main page]

PE20001583A1 - Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina - Google Patents

Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina

Info

Publication number
PE20001583A1
PE20001583A1 PE2000000241A PE0002412000A PE20001583A1 PE 20001583 A1 PE20001583 A1 PE 20001583A1 PE 2000000241 A PE2000000241 A PE 2000000241A PE 0002412000 A PE0002412000 A PE 0002412000A PE 20001583 A1 PE20001583 A1 PE 20001583A1
Authority
PE
Peru
Prior art keywords
pyrrolidine
alkyl
phenyl
toluen
arenosulfonil
Prior art date
Application number
PE2000000241A
Other languages
English (en)
Inventor
Eric Vieira
Jurgen Wichmann
Vincent Mutel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20001583A1 publication Critical patent/PE20001583A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1-ARENOSULFONIL-2-ARILO-PIRROLIDINA Y PIPERIDINA DE FORMULA I, DONDE: R1 ES H, ALQUILO, HIDROXIALQUILO; R2 ES FURILO, TIENILO, PIRIDILO, FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO, ALCOXILO, HALOGENO, CIANO, CF3, N(R4)2; R3 ES NAFTILO, FENILO OPCIONALMENTE SUSTITUIDO CON ALQUILO, ALCOXILO, HALOGENO, ACETILO, CIANO, HIDROXILO-ALQUILO, ALQUILO-N(R4)2, ENTRE OTROS; R4 ES H, ALQUILO; CON LA EXCEPCION DEL (RS)-2-FENIL-1-(TOLUEN-4-SULFONIL-PIRROLIDINA, (RS)-1-(TOLUEN-4-SULFONIL)-2-p-TOLIL-PIRROLIDINA. SON COMPUESTOS PREFERIDOS (RS)-2-(3-FLUOR-FENIL)-1-(TOLUEN-4-SULFONIL)-PIRROLIDINA, (RS)-1-(4-CLORO-BENCENOSULFONIL)-2-(3-FLUOR-FENIL)-PIRROLIDINA, (RS)-1-(4-CLORO-BENCENOSULFONIL)-2-FENIL-PIRROLIDINA, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS I SON ANTAGONISTAS O AGONISTAS DEL RECEPTOR METABOTROPICO DE GLUTAMATO POR LO QUE PUEDEN SER UTILES EN LA PREVENCION Y TRATAMIENTO DE TRASTORNOS NEUROLOGICOS COMO PSICOSIS, ESQUIZOFRENIA, ALZHEIMER, TRASTORNOS CONGNITIVOS
PE2000000241A 1999-03-25 2000-03-20 Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina PE20001583A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99106004 1999-03-25

Publications (1)

Publication Number Publication Date
PE20001583A1 true PE20001583A1 (es) 2001-01-15

Family

ID=8237852

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000241A PE20001583A1 (es) 1999-03-25 2000-03-20 Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina

Country Status (34)

Country Link
US (1) US6284785B1 (es)
EP (1) EP1165510B1 (es)
JP (1) JP3590589B2 (es)
KR (1) KR100452648B1 (es)
CN (1) CN1150165C (es)
AR (1) AR028817A1 (es)
AT (1) ATE305451T1 (es)
AU (1) AU765212B2 (es)
BR (1) BR0009278A (es)
CA (1) CA2368418C (es)
CO (1) CO5050296A1 (es)
CZ (1) CZ20013402A3 (es)
DE (1) DE60022867T2 (es)
DK (1) DK1165510T3 (es)
ES (1) ES2249249T3 (es)
HK (1) HK1044944B (es)
HR (1) HRP20010682A2 (es)
HU (1) HUP0200284A3 (es)
IL (1) IL145301A0 (es)
JO (1) JO2274B1 (es)
MA (1) MA26779A1 (es)
MX (1) MXPA01009623A (es)
MY (1) MY125295A (es)
NO (1) NO319948B1 (es)
NZ (1) NZ514037A (es)
PE (1) PE20001583A1 (es)
PL (1) PL204436B1 (es)
RU (1) RU2248350C2 (es)
SI (1) SI1165510T1 (es)
TR (1) TR200102789T2 (es)
TW (1) TW575561B (es)
WO (1) WO2000058285A1 (es)
YU (1) YU67601A (es)
ZA (1) ZA200107689B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1295561A (zh) 1998-06-03 2001-05-16 Gpinil控股公司 N-杂环羧酸或羧酸等排物的n-结合氨磺酰
US6589978B2 (en) 2000-06-30 2003-07-08 Hoffman-La Roche Inc. 1-sulfonyl pyrrolidine derivatives
US20040267010A1 (en) * 2001-02-02 2004-12-30 Forbes Ian Thomson Sulfonamide compounds, their preparation and use
TW200302717A (en) * 2002-02-06 2003-08-16 Schering Corp Novel gamma secretase inhibitors
WO2005030128A2 (en) * 2003-09-23 2005-04-07 Merck & Co., Inc. Pyrazole modulators of metabotropic glutamate receptors
CA2555399A1 (en) * 2004-02-20 2005-09-01 Novartis Ag Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders
EP1758884A2 (en) * 2004-05-20 2007-03-07 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
NZ566378A (en) 2005-08-30 2011-03-31 Takeda Pharmaceutical 1-Heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス,インコーポレイティド アンジオテンシン調節による神経新生
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
KR20090064418A (ko) 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
US8969387B2 (en) 2008-08-27 2015-03-03 Takeda Pharmaceutical Company Limited Pyrrole compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
US10603313B2 (en) 2017-07-31 2020-03-31 Chiromics, LLC Allosteric modulators of the mu opioid receptor
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK167393B1 (da) * 1985-12-30 1993-10-25 Roussel Uclaf 1-sulfonyl-2-oxo-pyrrolidinderivater, deres fremstilling og farmaceutiske praeparater med indhold deraf
US5194439A (en) * 1990-04-06 1993-03-16 John Wyeth & Brother Limited N-(2,3-dihydro-1,4-benzodioxinyl)-N-substituted aminopyrido-fused cycloalkanes
DE69205287T2 (de) * 1991-12-18 1996-03-14 Schering Corp., Kenilworth, N.J. Imidazolylalkyl- piperazin und -diazepin derivate als histamin h3 agonisten/antagonisten.
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
GB9612884D0 (en) * 1996-06-20 1996-08-21 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
JO2274B1 (en) 2005-04-07
PL204436B1 (pl) 2010-01-29
HUP0200284A3 (en) 2003-04-28
ZA200107689B (en) 2002-12-18
ES2249249T3 (es) 2006-04-01
YU67601A (sh) 2004-09-03
TW575561B (en) 2004-02-11
CZ20013402A3 (cs) 2002-03-13
EP1165510A1 (en) 2002-01-02
AR028817A1 (es) 2003-05-28
RU2248350C2 (ru) 2005-03-20
NZ514037A (en) 2004-01-30
HK1044944A1 (en) 2002-11-08
JP2002540191A (ja) 2002-11-26
PL350679A1 (en) 2003-01-27
MY125295A (en) 2006-07-31
NO319948B1 (no) 2005-10-03
AU3291500A (en) 2000-10-16
MXPA01009623A (es) 2002-05-06
CN1150165C (zh) 2004-05-19
NO20014617L (no) 2001-09-24
MA26779A1 (fr) 2004-12-20
SI1165510T1 (sl) 2005-12-31
HK1044944B (zh) 2004-10-21
KR100452648B1 (ko) 2004-10-12
EP1165510B1 (en) 2005-09-28
HRP20010682A2 (en) 2002-10-31
TR200102789T2 (tr) 2002-04-22
CA2368418C (en) 2009-03-10
BR0009278A (pt) 2001-12-26
DE60022867D1 (de) 2006-02-09
WO2000058285A1 (en) 2000-10-05
CA2368418A1 (en) 2000-10-05
CN1345311A (zh) 2002-04-17
IL145301A0 (en) 2002-06-30
AU765212B2 (en) 2003-09-11
US6284785B1 (en) 2001-09-04
JP3590589B2 (ja) 2004-11-17
DK1165510T3 (da) 2006-02-06
DE60022867T2 (de) 2006-06-22
HUP0200284A2 (en) 2002-06-29
NO20014617D0 (no) 2001-09-24
ATE305451T1 (de) 2005-10-15
CO5050296A1 (es) 2001-06-27
KR20010108403A (ko) 2001-12-07

Similar Documents

Publication Publication Date Title
PE20001583A1 (es) Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina
PE20020506A1 (es) Derivados de pirazol fusionados como inhibidores de la proteina cinasa
PE20030119A1 (es) Derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6
EE200100556A (et) Diarüülhappe derivaat, seda sisaldav farmatseutiline kompositsioon ja ühendi kasutamine ravimite valmistamiseks
FI970148A0 (fi) Heterosyklisten yhdisteiden käyttö dopamiini-D3-ligandeina
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
PA8467101A1 (es) Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orli
EA200101203A1 (ru) Производные пурина
NO20000572L (no) Indolderivater som MCP-1 reseptor antagonister
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
PE20060298A1 (es) Derivados de acido carboxilico de bencimidazolona
DK1200426T3 (da) Substituerede thien-3-yl-sulfonylamino(thio)carbonyl-tiazolin(thi)oner
PE68799A1 (es) Derivados de tetrahidroisoquinolina como moduladores del receptor de d3 de dopamina
TR200001906T2 (tr) Koks-Inhibitörleri olarak 2,3-ikameli indol bileşikleri.
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
NO20001483L (no) Nye NPY-agonister
PE20040698A1 (es) Derivados de isoindolina
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
ATE377602T1 (de) Morphinanderivate und ihre medizinische anwendung
PE20001084A1 (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
PT810220E (pt) Derivados de arilacrilamida como agonistas ou antigonistas de 5ht1
PE20000329A1 (es) Derivados de indol y composiciones farmaceuticas que los contienen
ES2180573T3 (es) Uso de derivados de indol como antagonistas de 5ht1.
DK0902018T3 (da) 2-(arylpheny)amino-imidazolinderivater

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed